You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Is it Time to Rethink the Maintenance of HIV-1 Virologic Suppression?

Watch ViiV Healthcare's webinar on "Is it time to rethink the maintenance of HIV-1 virologic suppression?"

In this online session you will hear from Professor Andrew Zolopa and Dr. Kimberly Smith on why DTG+RPV is now able to challenge a 20-year convention of traditional 3-drug regimens for virologically suppressed patients, reducing ARV exposure and potential associated toxicities. The speakers will summarise the SWORD studies and debate a patient case study, questioning why suppressed patients should take more ARVs than they need?

Go to Close Top

Chapter 1: Introduction

Presented by Professor Andrew Zolopa
Head North American Medical Affairs,
ViiV Healthcare.

01.05 mins

 

Chapter 2: Virologically Suppressed Patients Today

Presented by Professor Andrew Zolopa
Head North American Medical Affairs,
ViiV Healthcare.

03.24 mins

 

Chapter 3: Clinical Trial Data

Presented by Dr. Kimberly Smith
Vice President and Head, Global Research and Medical Strategy,
ViiV Healthcare.

22.25 mins

 

Chapter 4: Case Discussion

Presented by Professor Andrew Zolopa
Head North American Medical Affairs,
ViiV Healthcare.

08.55 mins

Video player requires JavaScript enabled. You can download this video here: http://edgesuite.gskstatic.com/HealthSites/Health/Ireland/HCP/MP4/ViiVDC-VDO-IRL-2018-0508_003_d4.mp4

Learn More about the 2-Drug Regimen Era

 

JULUCA is indicated for the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable ARV regimen for ≥6 months with no history of virological failure and no known or suspected resistance to any NNRTI or INI.

Juluca

(dolutegravir/rilpivirine)

Product information

Prescribing information

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trademarks are owned by or licensed to the ViiV Healthcare group of companies.